Summit Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Summit Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About SMMT
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI).
CEOMahkam Zanganeh
CEOMahkam Zanganeh
Employees159
Employees159
HeadquartersMiami, Florida
HeadquartersMiami, Florida
Founded2003
Founded2003
Employees159
Employees159
SMMT Key Statistics
Market cap14.65B
Market cap14.65B
Price-Earnings ratio-15.85
Price-Earnings ratio-15.85
Dividend yield—
Dividend yield—
Average volume2.11M
Average volume2.11M
High today$20.19
High today$20.19
Low today$18.88
Low today$18.88
Open price$18.99
Open price$18.99
Volume2.83M
Volume2.83M
52 Week high$36.91
52 Week high$36.91
52 Week low$15.55
52 Week low$15.55
Stock Snapshot
With a market cap of 14.65B, Summit Therapeutics(SMMT) trades at $19.50. The stock has a price-to-earnings ratio of -15.85.
During the trading session on 2026-01-10, Summit Therapeutics(SMMT) shares reached a daily high of $20.19 and a low of $18.88. At a current price of $19.50, the stock is +3.3% higher than the low and still -3.4% under the high.
Trading activity shows a volume of 2.83M, compared to an average daily volume of 2.11M.
The stock's 52-week range extends from a low of $15.55 to a high of $36.91.
The stock's 52-week range extends from a low of $15.55 to a high of $36.91.
Analyst ratings
81%
of 16 ratingsBuy
81.3%
Hold
18.8%
Sell
0%
People also own
Based on the portfolios of people who own SMMT. This list is generated using Robinhood data, and it’s not a recommendation.